不同禁食模式防治代谢相关脂肪性肝病的现状及思考

关键词：代谢相关脂肪性肝病；禁食；治疗学

基金项目：第二届全国名中医传承工作室建设项目（国中医药办人教函[2022]245号）；河南省中医药传承与创新人才工程第二批拔尖人才资助项目（豫卫中医函[2021]15号）；河南省中医药科学研究专项（2023ZXZX1061）；河南省中医学"双一流"创建科学研究专项（HSRP-DFCTCM-2023-6-02）

Current status and reflections on the preventionand treatment of metabolic associated fatty liver disease through different fasting patterns

CHEN Huaxin I，2 ， ZHAO Wenxia²，YUAN Jiachen ωil，2 ， ZHENG Yuzhu I，2 ，HAO Yaokun²，LIU Xiaoyan²

1.TheFirstClinicalMedicalCollgefHenanUniversityofChineseMedicine，Zhengzhou450ooo，China；2.DepartmentofSpleen， StomachLedldderestAfledsitalofUesitodie，Zgo

Correspondinguthors：LIU Xiaoyanliuxiaoyan0917@126.com（ORCID：009-02-7347-9318）；ZHAO Wenxia，zhao-wenia@ 163.c0m（0RCID：0000-0002-0592-3504）

Abstract：The incidencerateof metabolicasociatedfatt liverdisease（MAFLD）is graduall increasing，andithas becomea commonchronicliverdiseaseglobally.MAFLDiscloselyassociatedwithmetabolicdysfunction，withdietaryandexercise interventionsastheprimarytreatment method，amongwhichdietarycontrolisof particularimportance.Thisarticlesummarizes relatedarticlesonthepreventionandtreatmentofMAFLDthrough diferentfasting pattrns inrecentyears，andtheanalysis showed thatbyrestrictingfood intakeandcontrolingcalorieconsumption，fasting therapycanhelp toreducebodyweightand improve metabolicdisordersFurther studiesand clinical practiceare nededto exploreandvalidate the valueof diferentfasting patterns in the prevention and treatment of MAFLD.

KeyWords：Metabolic-Associated FattyLiver Disease；Fasting；Therapeutics

Researchfunding：TheSecondNational Famous Traditional ChineseMedicineInheritance Studio ConstructionProject（National MedicalOficeEducationLeter2O22]No.245））；FundingProjectfortheSecondBatchofTopTalentsintheInheritanceandInovation TalentProgramofTraditioalChnese MedicineinHenanProvice（YuHealthCommisionTCMLeter2O1]No.15）；SpecialProject of Traditional Chinese MedicineScientificResearchinHenanProvince（223ZXZX1061）；ScientificResearch Projectofthe“FistRate Universities and Disciplines”of Traditional Chinese Medicinein Henan Province（HSRP-DFCTCM-2023-6-02）

代谢相关脂肪性肝病（metabolic-associatedfattyliverdisease，MAFLD）是指代谢功能障碍导致肝脏脂肪变性积累超过 5% 的疾病，目前MAFLD全球患病率为 38.77%[1] 是全球最常见的慢性肝病之一，其疾病谱包括脂肪性肝病、代谢相关脂肪性肝炎（metabolic-associated steatohepatitis，MASH）及其相关纤维化、肝硬化和肝细胞癌（HCC）[2]MAFLD曾用名为非酒精性脂肪性肝病（NAFLD），近年来国际与中华医学会肝病学分会已将NAFLD重命名为MAFLD[2-3]。（剩余18586字）